Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoFOREWORD
Ver el documentoGLOSSARY*
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Ver el documentoII.1 Products
Abrir esta carpeta y ver su contenidoII.2 Substances Existing in Nature
Abrir esta carpeta y ver su contenidoII.3 Uses
Cerrar esta carpetaII.4 Methods for Treatment and Diagnostics
Ver el documentoII.4.1 Options - Methods
Ver el documentoII.5 Traditional Medicines
Abrir esta carpeta y ver su contenidoIII. SCOPE OF CLAIMS
Abrir esta carpeta y ver su contenidoIV. PATENTABILITY REQUIREMENTS
Abrir esta carpeta y ver su contenidoV. SPECIAL CASES IN PHARMACEUTICALS
Abrir esta carpeta y ver su contenidoVI. DISCLOSURE
Abrir esta carpeta y ver su contenidoVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Abrir esta carpeta y ver su contenidoVIII. EXAMINATION AND OBSERVATION PROCEDURES
Abrir esta carpeta y ver su contenidoIX. CLAIMS INTERPRETATION
Abrir esta carpeta y ver su contenidoX. COMPULSORY LICENSING
Ver el documentoXI. FINAL REMARKS
Ver el documentoREFERENCES
Ver el documentoBACK COVER

II.4.1 Options - Methods

A typical exclusion from patentability, as contained in many laws in force, may contain the following:

Diagnostic, Therapeutical and Surgical Methods
Model Option

Patents shall not be granted in respect of diagnostic, therapeutic and surgical methods for the treatment of humans and animals.

It should be noted that, even in the absence of specific provisions excluding the patentability of the referred methods, they may be deemed non eligible for protection due to the lack of industrial applicability, one of the essential requirements for patentability (see Section IV.3 below).

If the patentability of such methods were, however, admitted by national laws, its implications for the supply of health services should be assessed. Diagnostic, therapeutic and surgical patents, even if rarely granted, may negatively affect low-income patients’ access to required treatments, particularly in new areas such as gene-therapy59.

59 Though the gene therapy methods may not be patentable as such (if the suggested exclusion is provided for) the vectors and constructs that may be used could be patentable, as well as ex vivo process steps not involving the administration of the transformed cells to the patient (Grubb, 1999, p. 244).

In any case, the non-patentability of methods would not affect the patentability of equipments and substances necessary to execute them60.

60 In cases where the protection of such equipments and/or substances could lead to a de facto monopolization of the non-patented method, governments may have recourse to compulsory licenses, See Section X below.

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019